Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal or above 35 years;~* Diagnosis of type 2 diabetes mellitus as defined by the American Diabetes Association , with at least one year of disease duration at the time of the screening visit;~* Blood glucose lowering treatment with Metformin alone (monotherapy) at a stable dose of at least 1.5 g/day (or maximum tolerated dose) in the 3 months prior to the screening visit;~* Insufficient metabolic control as defined by recent (last six months) HbA1c ≥ 7% in any peripheral laboratory and confirmed at the time of the screening;~* Absence of a recent clinically-relevant progression of micro- and macro-vascular complications (see exclusion criteria);~* Written informed consent to participate to the study.~Exclusion criteria:~* Age below 35 years~* Type 1 diabetes or other causes of diabetes (pancreatectomy, gestational diabetes, etc.)~* HbA1c \< 7% or ≥ 9% at the screening visit~* Treatment with any blood glucose lowering treatment other than Metformin in the six months before screening visit~* BMI \< 20 or ≥ 40 kg/m2, or current/ past history of clinically-relevant eating disorders (including -but no limited to- nervous anorexia, bulimia, binge-eating disorders, etc.)~* Significant progression of diabetic macro-angiopathy or cardiovascular disease in the six months prior to study visit~* Significant progression of diabetic micro-angiopathy in the six months prior to study visit~* Organ failure or other severe diseases limiting life expectancy;~* Beginning, in the three months before screening visit, of any kind of drug which can modify glycemic levels (beta-blockers, diuretics...), or acute disease (acute infection, urinary tract infection...) in three months before screening visit~* History of inflammatory/infective/autoimmune chronic disease~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, gastric surgery, inflammatory bowel disease;~* Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at screening that in the judgment of the investigator would preclude safe completion of the study;~* Uncontrolled or inadequately controlled hypertension at screening (Systolic Blood Pressure (SBP)\>190 or Diastolic Blood Pressure (DBP) \>100 mmHg)~* Ongoing pregnancy or absence of effective contraception in women with childbearing potential~* Contraindications to the maintenance of the background therapy (Metformin), including -but not limited to- chronic kidney failure or plasma creatinine concentrations \> 1.5 mg/dL, severe respiratory failure, etc.;~* Contraindications to the use of a Sulfonylurea;~* Contraindications to the use of a DPP-IV Inhibitor;~* Laboratory findings, or other disease conditions, at the screening visit that might interfere with study measurements:~  1. Hemoglobinopathy known to affect HbA1c assays;~ 2. Known chronic liver diseases, including HBV (hepatitis B virus) and HCV (hepatitis C virus) infection;~ 3. Liver makers (aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), Gamma-glutamyltransferase (GGT) , bilirubin) above 2 times the upper normal limit;~ 4. Amylase and/or lipase above 2 times the upper normal limit;~* Chronic use of systemic and/or inhaled corticosteroids (only topical corticosteroids are allowed);~* History of low compliance, clinically-relevant psychiatric disorders or any current/ historical finding suggesting the patient as inappropriate to follow the study procedures.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin & metformin (Type: EXPERIMENTAL): Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
- Glibenclamide & metformin (Type: ACTIVE_COMPARATOR): Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).